2025-10-09 - Analysis Report
Okay, here's an analysis of Schrodinger Inc. (SDGR) based on the data provided. The report is structured with key figures first, followed by analysis.

**Report on Schrodinger Inc. (SDGR)**

**0. Executive Summary:**

SDGR, a company specializing in computational drug discovery and materials science, has significantly underperformed the S&P 500. While recent price action shows a slight upward trend, negative profitability and a large expected return suggest caution. Analyst opinions are generally positive, but the company faces challenges in achieving consistent revenue and profitability growth.

**1. Performance vs. S&P 500 (VOO)**

*   **Key Figures:**
    *   SDGR Cumulative Return: -50.25%
    *   VOO Cumulative Return: 67.77%
    *   Absolute Divergence (Current): -117.2%
    *   Relative Divergence: 2.1

*   **Analysis:** SDGR has drastically underperformed the S&P 500 over the period considered. The current absolute divergence is -117.2%, indicating a substantial gap in returns. The relative divergence of 2.1 places SDGR near the bottom of its historical performance range relative to the S&P 500.

    *   **Company Overview:** Schrodinger Inc. is a company focused on revolutionizing drug discovery and materials science through its physics-based computational platform.

*   **Alpha, Beta Analysis:**

    | Year       | CAGR     | MDD      | Alpha    | Beta   | Cap(B) |
    |------------|----------|----------|----------|--------|--------|
    | 2020-2022  | -70.0%   | 78.2%    | -76.0%   | 0.0    | 1.4    |
    | 2021-2023  | -57.0%   | 81.0%    | -59.0%   | -0.0   | 2.6    |
    | 2022-2024  | 6.0%     | 81.0%    | -14.0%   | -0.0   | 1.4    |
    | 2023-2025  | 1.0%     | 82.6%    | -63.0%   | -0.0   | 1.5    |

    **Analysis:** The table reveals several concerning trends:

    *   **Negative CAGR:**  The Compound Annual Growth Rate (CAGR) is negative across most periods, indicating a decline in investment value over time.
    *   **High MDD:** The Maximum Drawdown (MDD) is consistently high, signifying substantial potential losses for investors.
    *   **Negative Alpha:** The Alpha values are significantly negative, implying that SDGR has underperformed relative to its benchmark (S&P 500), even after accounting for market risk.
    *   **Low Beta:** The Beta values are close to zero, suggesting that SDGR's price movements are not strongly correlated with the broader market.
**2. Recent Price Action:**

*   **Key Figures:**
    *   Current Price: \$20.72
    *   Previous Close: \$20.16
    *   Change: 2.78%
    *   5-day Moving Average: \$20.84
    *   20-day Moving Average: \$19.72
    *   60-day Moving Average: \$20.01

*   **Analysis:** The current price is above both the 20-day and 60-day moving averages, suggesting a potential short-term upward trend. The price increase of 2.78% from the previous close indicates positive momentum.

**3. Technical Indicators & Risk Assessment:**

*   **Key Figures:**
    *   Market Risk Indicator (MRI): 0.9 (Medium Investment Recommended)
    *   RSI: 57.83
    *   PPO: 0.81
    *   Recent (20-day) Relative Divergence Change: 1.4% (Positive Trend)
    *   Expected Return: -2863.9%

*   **Analysis:**
    *   **MRI:** An MRI of 0.9 suggests a "Medium Investment Recommended" risk level.
    *   **RSI:** The RSI of 57.83 is neutral, indicating neither overbought nor oversold conditions.
    *   **PPO:** The PPO of 0.81 indicates a slight upward trend in price momentum.
    *   **Delta_Previous_Relative_Divergence:** The recent increase in relative divergence suggests short-term outperformance compared to the S&P 500.
    *   **Expected Return:** The extremely negative expected return suggests significant potential underperformance relative to the S&P 500 in the long term. This may indicate underlying fundamental issues.
    *   **Sudden Price Change:** The recent price jump (change: 2.78%) indicates a potential catalyst affecting the stock.

*   **Hybrid Signal:** The hybrid signal suggests a "cash_0%_Buy 100% of cash" strategy, indicating a potentially favorable entry point based on the indicators.

**4. Recent News & Significant Events:**

*   **Headlines:**
    *   Argus Research Analysis
    *   Inducement Grants under Nasdaq Listing Rule
    *   Valuation Assessment by Simply Wall St.
    *   Potential Rally Prediction by Zacks
    *   Presentation at Morgan Stanley Global Healthcare Conference

*   **Analysis:** The news headlines are a mixed bag. Analyst coverage from Argus Research and Simply Wall St. suggests scrutiny of the company's valuation and prospects. The Zacks article highlights potential for a rally. The announcement of inducement grants is a fairly standard corporate action.

**4-2. Analyst Opinions:**

*   **Consensus:**
    *   Key: Buy
    *   Mean: 1.56 (Buy)
    *   Opinions: 10
    *   Target Price: \$27.00 (Avg) / \$33.00 (High) / \$19.00 (Low)

*   **Analysis:** Despite the underperformance, analyst consensus is generally positive, with a "Buy" rating. The average target price suggests significant upside potential. However, the wide range between the high and low target prices indicates uncertainty among analysts.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출   |
|------------|-------|--------|
| 2025-08-06 | -0.59 | 0.05 B$ |
| 2025-05-07 | -0.82 | 0.06 B$ |
| 2024-11-12 | -0.52 | 0.04 B$ |
| 2024-07-31 | -0.74 | 0.05 B$ |
| 2025-08-06 | -0.74 | 0.05 B$ |

*   **Analysis:** The earnings data shows consistent losses per share (EPS) and relatively stable revenue. The recurring negative EPS values highlight a lack of profitability.

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | \$0.05B  | 47.77%        |
| 2025-03-31   | \$0.06B  | 52.26%        |
| 2024-12-31   | \$0.09B  | 72.61%        |
| 2024-09-30   | \$0.04B  | 50.24%        |
| 2024-06-30   | \$0.05B  | 66.20%        |

Capital and Profitability:

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-06-30   | \$0.34B | -12.59%  |
| 2025-03-31   | \$0.37B | -16.01%  |
| 2024-12-31   | \$0.42B | -9.54%   |
| 2024-09-30   | \$0.45B | -8.49%   |
| 2024-06-30   | \$0.47B | -11.40%  |

*   **Analysis:** The company shows a decent profit margin, but revenues are not high enough to be net income-positive. The shrinking equity and ROE suggest declining profitability and efficiency in utilizing equity.

**7. Overall Summary & Conclusion:**

Schrodinger Inc. (SDGR) presents a mixed picture. While analyst opinions are generally positive and recent price action shows some upward momentum, the company's historical underperformance relative to the S&P 500, consistent losses, and negative expected return raise significant concerns. The company's high MDD, large negative Alpha, and the trend of declining equity and ROE are also notable risks. The increase of recent (20일) Relative Divergence may indicate short-term outperformance compared to the S&P 500.

**Recommendation:** Given the significant risks and negative profitability, investors should exercise caution. While the analyst consensus suggests potential upside, a thorough assessment of the company's fundamentals and future prospects is crucial before considering an investment. A small allocation might be considered if the investor has a high risk tolerance and believes in the company's long-term potential, but a larger allocation is not warranted based on the current data.
